Search Results - "Betschart, Claudia"
-
1
Target-Based Identification and Optimization of 5‑Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay
Published in Journal of medicinal chemistry (13-08-2020)“…Inappropriate activation of endosomal TLR7 and TLR8 occurs in several autoimmune diseases, in particular systemic lupus erythematosus (SLE). Herein, the…”
Get full text
Journal Article -
2
The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease
Published in Molecular neurodegeneration (22-06-2010)“…Huntington's disease (HD) is a progressive neurodegenerative disorder caused by a CAG repeat expansion within the huntingtin gene. Mutant huntingtin protein…”
Get full text
Journal Article -
3
Distinct effects of IPSU and suvorexant on mouse sleep architecture
Published in Frontiers in neuroscience (01-01-2013)“…Dual orexin receptor (OXR) antagonists (DORAs) such as almorexant, SB-649868, suvorexant (MK-4305), and filorexant (MK-6096), have shown promise for the…”
Get full text
Journal Article -
4
Kinetic properties of "dual" orexin receptor antagonists at OX1R and OX2R orexin receptors
Published in Frontiers in neuroscience (01-01-2013)“…Orexin receptor antagonists represent attractive targets for the development of drugs for the treatment of insomnia. Both efficacy and safety are crucial in…”
Get full text
Journal Article -
5
Huntingtin cleavage product A forms in neurons and is reduced by gamma-secretase inhibitors
Published in Molecular neurodegeneration (14-12-2010)“…The mutation in Huntington's disease is a polyglutamine expansion near the N-terminus of huntingtin. Huntingtin expressed in immortalized neurons is cleaved…”
Get full text
Journal Article -
6
Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture for the Treatment of Insomnia
Published in Journal of medicinal chemistry (10-10-2013)“…Dual orexin receptor (OXR) antagonists (DORAs) such as almorexant, 1 (SB-649868), or suvorexant have shown promise for the treatment of insomnias and sleep…”
Get full text
Journal Article -
7
Structure-Based and Property-Driven Optimization of N‑Aryl Imidazoles toward Potent and Selective Oral RORγt Inhibitors
Published in Journal of medicinal chemistry (12-12-2019)“…Retinoic acid receptor-related orphan receptor gamma-t (RORγt) is considered to be the master transcription factor for the development of Th17 cells that…”
Get full text
Journal Article -
8
Discovery of potent, orally bioavailable in vivo efficacious antagonists of the TLR7/8 pathway
Published in Bioorganic & medicinal chemistry letters (01-09-2020)“…[Display omitted] Antagonism of the Toll-like receptors (TLRs) 7 and TLR8 has been hypothesized to be beneficial to patients suffering from autoimmune…”
Get full text
Journal Article -
9
Discovery of the TLR7/8 Antagonist MHV370 for Treatment of Systemic Autoimmune Diseases
Published in ACS medicinal chemistry letters (10-08-2023)“…Toll-like receptor (TLR) 7 and TLR8 are endosomal sensors of the innate immune system that are activated by GU-rich single stranded RNA (ssRNA). Multiple…”
Get full text
Journal Article -
10
Structure-Based Optimization of a Fragment-like TLR8 Binding Screening Hit to an In Vivo Efficacious TLR7/8 Antagonist
Published in ACS medicinal chemistry letters (14-04-2022)“…Inappropriate activation of TLR7 and TLR8 is linked to several autoimmune diseases, such as lupus erythematosus. Here we report on the efficient…”
Get full text
Journal Article -
11
Discovery of 1H-pyrazolo[3,4-b]pyridines as potent dual orexin receptor antagonists (DORAs)
Published in Bioorganic & medicinal chemistry letters (01-12-2015)“…[Display omitted] Compound rac-1 was identified by high throughput screening. Here we report SAR studies and MedChem optimization towards the highly potent…”
Get full text
Journal Article -
12
Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapy
Published in Cell reports. Medicine (16-05-2023)“…Genetic and in vivo evidence suggests that aberrant recognition of RNA-containing autoantigens by Toll-like receptors (TLRs) 7 and 8 drives autoimmune…”
Get full text
Journal Article -
13
Structure-Based Design and Synthesis of Macroheterocyclic Peptidomimetic Inhibitors of the Aspartic Protease β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE)
Published in Journal of medicinal chemistry (27-07-2006)“…Based on the X-ray cocrystal structure of the Tang−Ghosh heptapeptide inhibitor 1 (OM00-3), a series of macroheterocyclic analogues were designed and…”
Get full text
Journal Article -
14
Macrocyclic BACE-1 inhibitors acutely reduce Aβ in brain after po application
Published in Bioorganic & medicinal chemistry letters (15-01-2010)“…Starting from macrocyclic peptidic BACE-1 inhibitor 1, brain permeation was optimized for this series using a MDRI–MDCK assay to lead to NB-216 and analogues…”
Get full text
Journal Article -
15
Structure-based design and synthesis of novel P2/P3 modified, non-peptidic β-secretase (BACE-1) inhibitors
Published in Bioorganic & medicinal chemistry letters (15-03-2010)“…Starting from peptidomimetic BACE-1 inhibitors, the P2 amino acid including the P2/P3 peptide bond was replaced by a rigid 3-aminomethyl cyclohexane carboxylic…”
Get full text
Journal Article -
16
-
17
Structure-based design and synthesis of macrocyclic peptidomimetic β-secretase (BACE-1) inhibitors
Published in Bioorganic & medicinal chemistry letters (01-03-2009)“…An X-ray co-crystal structure of 1 with BACE-1 allowed the design and syntheses of a series of macrocyclic analogues 3a– h. These inhibitors show improved…”
Get full text
Journal Article -
18
Discovery of 1 H -pyrazolo[3,4- b ]pyridines as potent dual orexin receptor antagonists (DORAs)
Published in Bioorganic & medicinal chemistry letters (01-12-2015)Get full text
Journal Article -
19
Macrocyclic peptidomimetic β-secretase (BACE-1) inhibitors with activity in vivo
Published in Bioorganic & medicinal chemistry letters (01-03-2009)“…The macrocyclic peptidic BACE-1 inhibitors 2a– c were optimized to the highly potent and selective inhibitor 3. This compound shows inhibition of BACE-1 in the…”
Get full text
Journal Article -
20
2-Cyano-pyrimidines: A New Chemotype for Inhibitors of the Cysteine Protease Cathepsin K
Published in Journal of medicinal chemistry (22-02-2007)“…Starting from the purine lead structure 1, a new series of cathepsin K inhibitors based on a pyrimidine scaffold have been explored. Investigations of P3 and…”
Get full text
Journal Article